MarketPulse

FDA alignment

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Inmune Bio Inc.

INmune Bio's Alzheimer's Trial Wins Spotlight as Model for Inflammation-Targeting Approach

INmune Bio's XPro trial gains recognition at AD/PD 2026 for innovative biomarker-enriched Alzheimer's approach, securing FDA approval to advance to Phase 2b/3 registrational studies.
INMBclinical trialAlzheimer's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Minerva Neurosciences, Inc.

Minerva Neurosciences Posts $293M Loss But Bolsters Cash Reserves for Schizophrenia Drug Trial

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.
NERVprivate placementPhase 3 trial